Today's Pharma Pipeline Boost: Three Strong Mid-Stage Results

Today’s pharma pipeline delivers three strong mid-stage results that energize the industry.

Major companies release positive Phase 2 data that open clear paths to Phase 3 trials.

Eli Lilly advances its amylin-tirzepatide combination, which drives superior weight loss and blood-sugar control against its own blockbuster Zepbound in patients who live with obesity and Type 2 diabetes.

Merck reports that tulisokibart meets its main goal in moderate-to-severe hidradenitis suppurativa.

AbbVie shows that zumilokibart produces meaningful skin clearance and itch relief in atopic dermatitis and selects the mid-dose for late-stage development.

These outcomes create shared momentum in next-generation obesity therapies and chronic inflammatory skin diseases on the same day, giving patients and investors fresh reasons for optimism.

Companies Delivering Latest Positive Trial Results

Three leading firms share strong mid-stage news today:

• Eli Lilly reports that its experimental combination of eloralintide (an amylin agonist) plus tirzepatide, known as EloraTZP, outperforms high-dose tirzepatide alone in a Phase 2 trial of patients with obesity and Type 2 diabetes. The company plans to start Phase 3 trials by the end of 2026.
• Merck announces that tulisokibart meets the primary endpoint in a mid-stage study of moderate-to-severe hidradenitis suppurativa, a chronic condition marked by painful lumps, abscesses, and scarring.
• AbbVie presents positive Phase 2 APEX Part B results for zumilokibart in moderate-to-severe atopic dermatitis as a late-breaker at EADV 2026 and advances the mid-dose regimen into Phase 3.

Also Read: How Deviation Trends Can Reveal Hidden Pharma Quality Risks

Key Achievements and Benefits for Patients

Each result delivers clear gains that can improve daily life for specific patient groups.

• Eli Lilly’s amylin-tirzepatide combination produces up to 23.3 percent average weight loss (about 54 pounds) at the highest dose after 48 weeks, compared with 14.8 percent for 15 mg tirzepatide alone. The same regimen lowers A1C by up to 2.9 percent versus 2.4 percent for tirzepatide.

Kenneth Custer, president of Lilly Cardiometabolic Health, notes that patients may not achieve what they need from tirzepatide or eloralintide alone, and the combination supplies even greater weight loss.

This multi-hormone approach can help people with obesity and Type 2 diabetes who struggle to lose sufficient weight or control blood sugar on existing GLP-1 medicines, offering a stronger alternative for those who need deeper results.

• Merck’s tulisokibart shows that 72 percent of patients on the highest dose achieve at least a 50 percent reduction in inflammatory skin lesions after 16 weeks, versus 35 percent on placebo. Up to 41 percent reach a tougher 75 percent reduction, compared with 15 percent on placebo.

Safety remains comparable between the drug and placebo groups. These reductions can ease the painful lumps, abscesses, and scarring that limit mobility and quality of life for people living with hidradenitis suppurativa.

• AbbVie’s zumilokibart, a half-life-extended IL-13 antibody, meets the primary endpoint of EASI-75 response at Week 16 across all three dose regimens versus placebo. The mid- and high-dose groups also deliver greater improvements in near-complete or complete skin clearance (EASI 90/100) and itch (I-NRS4).

The mid-dose produces greater percent reductions in skin severity by Week 1 and in itch by Week 2. Kori Wallace, vice president and global head of immunology clinical development at AbbVie, states that the results support zumilokibart’s potential to rapidly improve both skin and itch.

Melinda Gooderham, M.D. FRCPC, SKiN Centre for Dermatology and Queen's University, Ontario, Canada, adds that the findings support further evaluation of zumilokibart as a long-term treatment. Patients with moderate-to-severe atopic dermatitis can gain faster, more convenient control of lesions and itch, addressing a persistent unmet need.

Final Takeaway

These three strong mid-stage results strengthen the pipeline in two high-value areas and sharpen the competitive landscape.

Lilly’s combination raises the bar for obesity and diabetes care by targeting multiple natural hormone pathways at once, delivering deeper weight loss and better blood-sugar control for patients who need more than current GLP-1 options.

The data also position EloraTZP as a potential alternative for the many people who fail to reach their goals on existing therapies, while the company prepares optimized dosing for Phase 3 to improve the efficacy-tolerability balance.

Merck and AbbVie expand options for chronic inflammatory skin diseases that currently leave many patients underserved. Tulisokibart’s strong lesion reductions and comparable safety offer hidradenitis suppurativa patients a new path to meaningful relief, while zumilokibart’s rapid skin and itch improvements, plus an extended half-life, support more convenient long-term control in atopic dermatitis.

Together, the results clear paths to Phase 3, intensify rivalry in the growing obesity market, and move differentiated therapies closer to the people who need them most.